⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for grade 3b follicular lymphoma

Every month we try and update this database with for grade 3b follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.NCT03150329
Grade 3b Follic...
Recurrent B-Cel...
Recurrent Class...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Prima...
Recurrent Trans...
Refractory B-Ce...
Refractory Clas...
Refractory Diff...
Refractory Foll...
Refractory Prim...
Refractory Tran...
Laboratory Biom...
Pembrolizumab
Vorinostat
18 Years - City of Hope Medical Center
Expanded Access Program for EpcoritamabNCT05733650
Large B-cell Ly...
Diffuse Large B...
Primary Mediast...
High Grade B-ce...
Grade 3B Follic...
Epcoritamab
18 Years - Genmab
Expanded Access Program for EpcoritamabNCT05733650
Large B-cell Ly...
Diffuse Large B...
Primary Mediast...
High Grade B-ce...
Grade 3B Follic...
Epcoritamab
18 Years - Genmab
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaNCT04156828
Grade 3b Follic...
Recurrent Diffu...
Recurrent Folli...
Refractory Diff...
Non-Hodgkin's L...
Copanlisib
Gemcitabine
Carboplatin
Dexamethasone
Rituximab
Pegfilgrastim
18 Years - University of Washington
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT05633615
Diffuse Large B...
Grade 3b Follic...
Primary Mediast...
Recurrent Diffu...
Refractory Diff...
Transformed Fol...
Transformed Mar...
Axicabtagene Ci...
Biospecimen Col...
Computed Tomogr...
Cyclophosphamid...
Fludarabine
Lisocabtagene M...
Mosunetuzumab
Patient Observa...
Polatuzumab Ved...
Positron Emissi...
Tisagenlecleuce...
18 Years - SWOG Cancer Research Network
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaNCT05455697
Diffuse Large B...
Grade 3b Follic...
High Grade B-Ce...
Bone Marrow Bio...
Cyclophosphamid...
Doxorubicin
Prednisone
Retifanlimab
Rituximab and H...
Tafasitamab
Vincristine
Bone Marrow Asp...
Multigated Acqu...
Fludeoxyglucose...
Positron Emissi...
Computed Tomogr...
Biospecimen Col...
Polatuzumab Ved...
18 Years - University of Washington
Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular LymphomaNCT02541565
Composite Lymph...
Grade 3b Follic...
Stage I Diffuse...
Stage I Follicu...
Stage II Diffus...
Stage II Follic...
Stage III Diffu...
Stage III Folli...
Stage IV Diffus...
Stage IV Follic...
Cyclophosphamid...
Doxorubicin Hyd...
Laboratory Biom...
Pembrolizumab
Prednisone
Rituximab
Vincristine Sul...
18 Years - University of Washington
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.NCT03150329
Grade 3b Follic...
Recurrent B-Cel...
Recurrent Class...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Prima...
Recurrent Trans...
Refractory B-Ce...
Refractory Clas...
Refractory Diff...
Refractory Foll...
Refractory Prim...
Refractory Tran...
Laboratory Biom...
Pembrolizumab
Vorinostat
18 Years - City of Hope Medical Center
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)NCT00823719
Lymphoma, Large...
ofatumumab + IC...
ofatumumab + DH...
18 Years - GlaxoSmithKline
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaNCT02343536
Lymphoma, Large...
Lymphoma, Folli...
Oral Azacitidin...
Rituximab
cyclophosphamid...
Vincristine
Prednisone
18 Years - Celgene
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaNCT02343536
Lymphoma, Large...
Lymphoma, Folli...
Oral Azacitidin...
Rituximab
cyclophosphamid...
Vincristine
Prednisone
18 Years - Celgene
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaNCT04156828
Grade 3b Follic...
Recurrent Diffu...
Recurrent Folli...
Refractory Diff...
Non-Hodgkin's L...
Copanlisib
Gemcitabine
Carboplatin
Dexamethasone
Rituximab
Pegfilgrastim
18 Years - University of Washington
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaNCT05455697
Diffuse Large B...
Grade 3b Follic...
High Grade B-Ce...
Bone Marrow Bio...
Cyclophosphamid...
Doxorubicin
Prednisone
Retifanlimab
Rituximab and H...
Tafasitamab
Vincristine
Bone Marrow Asp...
Multigated Acqu...
Fludeoxyglucose...
Positron Emissi...
Computed Tomogr...
Biospecimen Col...
Polatuzumab Ved...
18 Years - University of Washington
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)NCT00823719
Lymphoma, Large...
ofatumumab + IC...
ofatumumab + DH...
18 Years - GlaxoSmithKline
An Italian Experience on Grade 3b Follicular LymphomaNCT02927717
Grade 3b Follic...
18 Years - Azienda Ospedaliera Città della Salute e della Scienza di Torino
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: